Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 1.00 |
| ▸ | F3 | P13726 | 20/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832858 | 1.00 | F7 (1.00) | F7F3PLG | |
| SCHEMBL2528781 | 1.00 | F7 (1.00) | F7F3PLG | |
| SCHEMBL3830262 | 0.94 | F7 (0.89) | F7F3PLG | |
| SCHEMBL2528444 | 0.94 | F7 (0.89) | F7F3PLG | |
| SCHEMBL2528445 | 0.94 | F7 (0.89) | F7F3PLG | |
| SCHEMBL2530506 | 0.94 | F7 (1.00) | F7F3PLG | |
| SCHEMBL3908282 | 0.94 | F7 (1.00) | F7F3PLG | |
| SCHEMBL2528735 | 0.91 | F7 (1.00) | F7F3PLG | |
| SCHEMBL2528732 | 0.91 | F7 (1.00) | F7F3PLG | |
| SCHEMBL3834872 | 0.91 | F7 (1.00) | F7F3PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| EP-2099783-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079759-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F8, F9 | F7 1/4885F3 12/4885PLG 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.